WhiteHawk Capital Provides Loan to Support Acquisition of Family Dollar

LOS ANGELES--(BUSINESS WIRE)-- WhiteHawk Capital Partners (“WhiteHawk”) has acted as lead and sole agent to provide a first-in, last-out (FILO) term loan to Family Dollar Stores, Inc. (“Family Dollar”), as part of a $1.5bn asset-based facility, to finance its acquisition by Brigade Capital Management, LP and Macellum Capital Management, LLC. On July 7, 2025, the closing of this transaction marks Family Dollar’s transition to new ownership after it was acquired by Dollar Tree, Inc. (NASDAQ: DLTR) in 2015.

Family Dollar is a leading U.S. discount retailer with more than 7,000 locations nationwide, offering customers a broad range of general merchandise.

“We’re proud to deliver this flexible capital solution to support the acquisition of Family Dollar,” said Alex Zuckerman, Managing Director at WhiteHawk. “This transaction reflects WhiteHawk’s commitment to providing tailored financing to businesses with strong fundamentals and significant growth potential.”

About WhiteHawk

WhiteHawk is a private credit investment manager focused on asset-based financing solutions primarily to middle market private and public companies across a variety of industries. WhiteHawk is dedicated to bringing creative and flexible non-traditional capital solutions to companies in need of liquidity and growth capital.

Since 2015, the firm’s professionals, at WhiteHawk and in prior capacities, have been providing asset-based loans to public and private middle-market companies facing liquidity challenges or in “out of favor” industries and, as of March 31, 2025, have collectively structured 91 loans with 68 realizations with $4.6 billion+ of gross loans originated. If you would like more information about WhiteHawk Capital or have any questions regarding the firm’s role in this transaction, please contact WhiteHawk at [email protected].

View source version on businesswire.com: https://www.businesswire.com/news/home/20250707011275/en/

[email protected]

Source: WhiteHawk Capital Partners

You May Also Be Interested In

• Ivonescimab Monotherapy Demonstrates a Statistically Significant & Clinically Meaningful Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in Akeso’s HARMONi-2 Study
• Ethereum Price Prediction – Can ETH Reach $3k While Apeing Surges as the Next Big Crypto with $80k Raised
• Apeing Presale Surpasses $80,000 as Stage 3 Progresses Toward Scheduled Stage 4 Launch